ONCR

Oncorus, Inc. [ONCR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ONCR Stock Summary

In the News

ONCR Financial details

Company Rating
-
Market Cap
3.29M
Income
-94.27M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
0.14
Dividend %
110.58%
Employees
64
Optionable
No
Shortable
Yes
Earnings
22 Mar 2024
P/E
-0.04
Forward P/E
-
PEG
-0.01
P/S
-
P/B
0.11
P/C
-
P/FCF
-0.06
Quick Ratio
1.45
Current Ratio
1.5
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.63
EPS next Y
-
EPS next Q
-
EPS this Y
17.97%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
54.22%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-68%
ROE
-131%
ROC
-0.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.01-0.47
52W High
-
52W Low
-
RSI
-
Rel Volume
1.25
Avg Volume
108.68K
Volume
135.95K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.954
-
-
Volatility
0%, 0%
Prev Close
4.56%
Price
0.126
Change
-

ONCR Financial Performance

ONCR Dividend History

ONCR Frequently Asked Questions

What is Oncorus, Inc. stock symbol ?

Oncorus, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol ONCR

What is Oncorus, Inc. stock quote today ?

Oncorus, Inc. stock price is $0.126 today.

Is Oncorus, Inc. stock public?

Yes, Oncorus, Inc. is a publicly traded company.

Something similar

Top by Market Cap
TL0.DE
V
MIX.JO
AAPL
DHR-PB
Same Sector
LALPATHLAB.NS
NEPH
4104.TW
SHWZ
ALTHX.PA
Check Those
MAR
GLIFX
0F2Z.L
83100.HK
NIRAJ.NS
Similar Market Cap
BAY.L
XPC.ST
TSOC
AMBO
VNMC

Company Profile

Healthcare Biotechnology
  • Volume Average 108.68K
  • Market Capitalization 3.29M
  • Employee 64
  • CEO Mr. Craig R. Jalbert CIRA
  • Headquarters Cambridge,MA,US
  • IPO Date 2020-10-02
  • Website https://www.oncorus.com

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.